Resting State Changes Following Theta Burst Stimulation
Transcranial magnetic stimulation (TMS) is increasingly being applied to effectively treat mental illness, however efforts to quantify the effects of TMS on the network architecture of the brain have largely been limited in scope and tied to specific neurologic and psychiatric disorders. The objective of the current wo
| Condition(s) | Brain Connectivity |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Transcranial magnetic stimulation (TMS) is increasingly being applied to effectively treat mental illness, however efforts to quantify the effects of TMS on the network architecture of the brain have largely been limited in scope and tied to specific neurologic and psychiatric disorders. The objective of the current work is to build and validate a whole-brain, domain-general model of brain connectivity changes following TMS, based on physical models of the current distribution at the cortex. PUBLIC HEALTH RELEVANCE: This work is relevant to public health because it will provide direct evidence that brain connectivity changes following neuromodulatory TMS vary as a function of the current density at the cortex, which can be used to predict psychiatric symptom change following neuromodulator |
| Who can participate | Inclusion Criteria * Able to give their consent * Right-handed Exclusion Criteria * Non-english speaking * Any significant medical problems * Current or past Axis I psychiatric disorder(s), * Active or history of active suicidal ideation * Alcohol/drug problems in the past year or lifetime alcohol or drug dependence * Medications that act on the central nervous system * History of seizure * History of epilepsy or other neurological problems * Increased risk of seizure for any reason * Pregnancy * Any medical condition that increases risk for fMRI or TMS * Any metal in their body which would make having an MRI scan unsafe * Any sort of medical implants * Claustrophobia |
| Ages | 18 Years to 60 Years |
| Sex | All |
| Accepts healthy volunteers | Yes |
| Lead sponsor | Nicholas Balderston, PhD |
| Locations | Philadelphia, Pennsylvania, United States |
| Start date | 2022-11-17 |
| NCT ID | NCT05322239 |
| Official listing | https://clinicaltrials.gov/study/NCT05322239 |